ESF2 Antibody

What is ESF2 protein and how does it function in cellular processes?

ESF2 (Essential for Splicing Factor 2) is a nucleolar protein that plays critical roles in RNA processing pathways. Research has demonstrated that ESF2 directly interacts with DExD/H box proteins, particularly Dbp8, and binds RNA in vitro . The protein contains a predicted RRM (RNA Recognition Motif) domain which facilitates its RNA-binding capabilities, though this binding appears to occur without apparent sequence specificity .

ESF2 is essential for cell viability, as demonstrated through depletion studies in yeast models. When endogenous ESF2 is depleted under a galactose-inducible/dextrose repressible promoter system, cellular growth is severely compromised . The functional importance of ESF2 appears particularly dependent on its C-terminal domain, which is essential for proper protein function and interaction with binding partners like Dbp8 .

What are the key experimental applications for ESF2 antibodies?

ESF2 antibodies serve numerous critical functions in molecular and cellular research, similar to other protein-specific antibodies like those targeting EF-2/EEF2 . Primary applications include:

• Western Blotting: For detecting and quantifying ESF2 protein expression in cell and tissue lysates

• Immunoprecipitation: Used in co-IP experiments to study protein-protein interactions, similar to experiments with tagged ESF2 variants that demonstrated interaction with Dbp8

• Immunohistochemistry/Immunocytochemistry: For visualizing ESF2 subcellular localization and expression patterns in tissues and cultured cells

• RNA Immunoprecipitation: Given ESF2's RNA-binding capabilities, antibodies can be used to isolate and identify RNA targets

• Protein-RNA interaction studies: For analyzing the binding characteristics between ESF2 and various RNA substrates, similar to experiments that demonstrated ESF2 binding to rRNA fragments

How do I select the appropriate ESF2 antibody for my specific research application?

When selecting an ESF2 antibody, consider these key factors based on general antibody principles and specific research applications:

How can I validate the specificity of my ESF2 antibody to ensure research integrity?

Rigorous validation is essential for antibody-based research. For ESF2 antibodies, implement these validation strategies:

• Genetic validation: Use ESF2 knockout/knockdown systems as negative controls. The galactose-inducible/dextrose repressible promoter system described for ESF2 provides an excellent model for antibody validation

• Epitope competition assays: Pre-incubate the antibody with purified ESF2 protein or peptide before immunostaining/immunoblotting to confirm specificity

• Multiple antibodies approach: Use antibodies targeting different ESF2 epitopes and compare detection patterns

• Recombinant expression systems: Test antibody against known quantities of recombinant ESF2, similar to the GST-ESF2 system described in the literature

• Domain-specific validation: If studying specific ESF2 domains (N-terminal, RRM, or C-terminal), validate using the deletion mutants described in the literature (ΔN, ΔRRM, ΔC)

• Binding affinity determination: Consider affinity binding assays to determine antibody-epitope binding kinetics (KD values), similar to those performed for other research antibodies

What experimental challenges should I anticipate when using ESF2 antibodies for localization studies?

ESF2 localization studies present several unique challenges that require careful experimental design:

• Nucleolar targeting: As a nucleolar protein, ESF2 visualization requires optimal nuclear and nucleolar permeabilization. Standard 4% paraformaldehyde fixation with 0.5% Triton X-100 permeabilization may be insufficient

• Co-localization markers: Include established nucleolar markers to confirm proper subcellular localization. Consider markers similar to those used in eEF2 localization studies that employed the ER marker calnexin

• Signal-to-noise optimization: Nuclear proteins often require more stringent blocking to minimize background (5% BSA or serum matching the secondary antibody host species)

• Stress-induced localization changes: Consider that stress conditions may alter ESF2 localization, similar to other proteins that undergo stress-triggered assembly . Design time-course experiments to capture dynamic changes

• Quantification approaches: For precise localization analysis, employ methods like Pearson's correlation coefficient to quantify co-localization with known markers, as used in eEF2 localization studies

How does ESF2 structure influence epitope selection and antibody performance?

ESF2 contains distinct domains that impact antibody selection and performance:

• The RRM domain: This RNA-binding motif may change conformation upon RNA binding, potentially masking antibody epitopes in RNA-bound states. Epitopes outside this domain may provide more consistent detection regardless of RNA binding status

• C-terminal domain: Critical for function and protein-protein interactions, particularly with Dbp8. Antibodies targeting this region may potentially interfere with protein-protein interactions in certain applications

• N-terminal region: This region appears less critical for ESF2 function, as N-terminal deletion mutants maintain functionality. Antibodies targeting this region may therefore be less likely to interfere with native protein function

• Conformational considerations: Consider that ESF2 may undergo conformational changes during stress or after binding to partners like Dbp8, potentially affecting epitope accessibility

What is the optimal protocol for detecting ESF2 in Western blot applications?

Based on protocols for similar proteins and general Western blotting principles:

• Sample preparation:

  • Extract proteins using RIPA buffer supplemented with protease inhibitors

  • For nucleolar proteins like ESF2, consider specialized nuclear extraction protocols

  • Include phosphatase inhibitors if phosphorylation status is important

• Gel electrophoresis:

  • Use 10-12% SDS-PAGE gels for optimal resolution

  • Load appropriate positive controls (e.g., cell lines known to express ESF2)

• Transfer and detection:

  • Transfer to PVDF membrane (preferred for nuclear proteins)

  • Block in 5% non-fat dry milk or BSA in TBST

  • Incubate with primary ESF2 antibody at 1:1,000 dilution (similar to dilutions used for EF-2/EEF2 antibodies)

  • Use appropriate HRP-conjugated secondary antibody (1:5,000-1:10,000)

• Optimization tips:

  • If signal is weak, consider overnight primary antibody incubation at 4°C

  • For nucleolar proteins, longer transfer times may be necessary

  • Validate bands using positive controls and predicted molecular weight

How can I establish a robust co-immunoprecipitation protocol to study ESF2 protein interactions?

For studying interactions similar to the ESF2-Dbp8 complex :

• Lysate preparation:

  • Harvest cells in non-denaturing lysis buffer (150 mM NaCl, 50 mM Tris pH 7.5, 0.5% NP-40)

  • Include protease inhibitors and, if relevant, phosphatase inhibitors

  • Clear lysate by centrifugation (14,000g, 10 minutes, 4°C)

• Immunoprecipitation:

  • Pre-clear lysate with protein A/G beads (1 hour, 4°C)

  • Incubate cleared lysate with ESF2 antibody overnight at 4°C

  • Add protein A/G beads and incubate 2-3 hours at 4°C

  • Wash 4-5 times with lysis buffer

  • Elute with SDS sample buffer

• Controls and validation:

  • Include IgG control to assess non-specific binding

  • Perform reciprocal IP with antibodies against suspected interaction partners

  • Validate interactions with different antibodies or tagged constructs

  • Consider RNase treatment to determine RNA-dependency of interactions, particularly relevant for RNA-binding proteins like ESF2

What strategies can address common problems in ESF2 RNA-binding studies using antibodies?

Given ESF2's demonstrated RNA-binding capabilities , these approaches can optimize RNA-protein interaction studies:

• RNA immunoprecipitation (RIP) optimization:

  • Cross-linking conditions are critical: test both formaldehyde (1%) and UV cross-linking

  • Include RNase inhibitors throughout all procedures

  • Validate RNA integrity before and after immunoprecipitation

  • Compare various lysis conditions to maintain RNA-protein complexes

• Competition assays:

  • Similar to experiments with GST-ESF2, test binding to various RNA fragments

  • Include unlabeled competitor RNA to assess binding specificity

  • Evaluate binding to different RNA classes (rRNA, mRNA, tRNA)

• Quantification approaches:

  • Use RT-qPCR to quantify co-precipitated RNAs

  • For transcriptome-wide analysis, consider RIP-seq approaches

  • Validate findings with in vitro binding assays using recombinant protein

• Troubleshooting weak signals:

  • Increase crosslinking efficiency

  • Optimize antibody concentration and incubation conditions

  • Reduce washing stringency to preserve weaker interactions

  • Consider epitope accessibility in RNA-bound vs. unbound states

How can ESF2 antibodies be utilized to investigate stress-response pathways?

ESF2 antibodies can provide valuable insights into stress-response mechanisms, drawing on principles from related research :

• Stress-induced localization changes:

  • Use immunofluorescence with ESF2 antibodies to track protein relocalization during stress

  • Compare various stressors (heat shock, oxidative stress, nutrient deprivation)

  • Quantify temporal dynamics of ESF2 redistribution during stress and recovery

• Stress granule association:

  • Co-stain with stress granule markers to determine if ESF2 associates with these structures

  • Analyze protein-protein interactions that may be stress-dependent

  • Consider the relationship between translation regulation and ESF2 function during stress

• Experimental design considerations:

  • Include appropriate time-course analysis (acute vs. chronic stress)

  • Consider cell-type specific responses

  • Compare wild-type and mutant ESF2 behavior under stress conditions

• Data interpretation guidelines:

  • Distinguish between specific stress responses and general cellular damage

  • Consider both qualitative (localization changes) and quantitative (expression level) alterations

  • Correlate ESF2 behavior with functional outcomes (e.g., translation efficiency, cell viability)

What approaches can resolve contradictory findings in ESF2 antibody-based experiments?

When facing contradictory results with ESF2 antibodies:

• Antibody validation reassessment:

  • Confirm antibody specificity through knockout/knockdown controls

  • Test multiple antibodies targeting different ESF2 epitopes

  • Verify detection of both endogenous and overexpressed protein

• Experimental condition variations:

  • Evaluate fixation effects (paraformaldehyde vs. methanol) on epitope accessibility

  • Consider cell type-specific differences in ESF2 expression or localization

  • Assess potential interference from post-translational modifications

• Technical approach diversification:

  • Complement antibody-based methods with alternative techniques:

    • Fluorescent protein tagging for live-cell imaging

    • Mass spectrometry for protein identification

    • RNA-seq for functional impact assessment

• Reconciliation strategies:

  • Map contradictory findings to specific domains or functions of ESF2

  • Consider context-dependent interactions or conformational changes

  • Develop unified models that incorporate seemingly contradictory observations

How can I design experiments to dissect the functional domains of ESF2 using antibody-based methods?

Building on the domain analysis approaches mentioned in the search results :

How can emerging technologies enhance ESF2 antibody applications in research?

Emerging technologies offer new opportunities for ESF2 antibody applications:

• Advanced imaging approaches:

  • Super-resolution microscopy for precise subcellular localization

  • Live-cell antibody-based imaging using cell-permeable antibody fragments

  • Correlative light and electron microscopy to connect ESF2 localization with ultrastructural features

• High-throughput analysis methods:

  • Antibody-based proteomics using protein arrays

  • Single-cell analysis of ESF2 expression and localization heterogeneity

  • Automated image analysis pipelines for quantitative assessment of localization changes

• Structural biology integration:

  • Cryo-EM studies of ESF2-containing complexes with antibody-based purification

  • Integration of AI-driven modeling approaches similar to those described for antibody-antigen complexes

  • Structure-guided antibody development for specific functional domains

• Therapeutic implications:

  • Development of antibody-based tools to modulate ESF2 function in disease models

  • Target validation using intrabodies (intracellular antibodies)

  • Exploration of ESF2 pathway perturbations in disease contexts

What are the most promising directions for ESF2 research using antibody-based approaches?

Based on current knowledge about ESF2 and related proteins:

• Stress response mechanisms:

  • Investigation of ESF2's potential role in stress adaptation

  • Analysis of how RNA-binding properties may change under stress conditions

  • Correlation between ESF2 function and translation regulation during stress

• Ribosome biogenesis pathways:

  • Further characterization of ESF2's role in RNA processing

  • Analysis of interaction networks in nucleolar function

  • Exploration of potential disease relevance in ribosomopathies

• Evolutionary conservation studies:

  • Comparative analysis of ESF2 function across species using cross-reactive antibodies

  • Investigation of domain-specific functions in different organisms

  • Analysis of how ESF2 networks have evolved

• Disease-relevant investigations:

  • Exploration of ESF2 in cellular models of neurodegeneration, drawing on approaches used in SCA26 studies with EEF2

  • Analysis of cancer-relevant alterations in ESF2 function

  • Development of ESF2-targeted therapeutic approaches